Compare Amphastar Pharmaceuticals Inc (AMPH) vs Innodata Inc (INOD) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

INOD trades at $67.80, down 1.99% amid bearish technical signals despite strong fundamental performance. The stock shows robust revenue growth with 2025 revenue of $251.66M and net income of $32.18M, supported by consistent earnings beats. Analyst consensus remains bullish with a $130 price target, though recent insider selling and technical weakness create near-term pressure.

Outlook remains positive given AI-driven growth potential and strong profitability metrics, but investors face volatility risks from high valuation multiples and competitive pressures in the AI data services space. The stock's current pullback presents a potential entry point for long-term investors believing in the AI growth story.